CurrentCardio
@currentcardio.com
Structured summaries of new cardiovascular studies from the leading journals. Launching soon.
PREMIUM NEJM: prasugrel monotherapy vs aspirin + prasugrel in STEMI undergoing primary PCI. n=2216, 12 mo
Death, stroke or MI:
11.0% vs 8.5%
HR 1.34 (95% CI 1.02–1.75)
Noninferiority not established (P=0.40)
Death, stroke or MI:
11.0% vs 8.5%
HR 1.34 (95% CI 1.02–1.75)
Noninferiority not established (P=0.40)
October 3, 2026 at 8:45 AM
PREMIUM NEJM: prasugrel monotherapy vs aspirin + prasugrel in STEMI undergoing primary PCI. n=2216, 12 mo
Death, stroke or MI:
11.0% vs 8.5%
HR 1.34 (95% CI 1.02–1.75)
Noninferiority not established (P=0.40)
Death, stroke or MI:
11.0% vs 8.5%
HR 1.34 (95% CI 1.02–1.75)
Noninferiority not established (P=0.40)
Semaglutide in T2D: a bone marrow effect? (n=16, before–after, 6 months)
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
Potential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes
AbstractBackground and Aims. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have ant
doi.org
October 2, 2026 at 9:47 AM
Semaglutide in T2D: a bone marrow effect? (n=16, before–after, 6 months)
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
GBD 2023, heart failure: estimated 56.0 million cases in 2023 (24.9 million in 1990)
All-ages prevalence +124.6%
Age-standardised +2.7% (95% UI −0.6 to 5.8)
Leading etiologies: ischaemic HD 33.7%, hypertensive HD 23.8%, other cardiomyopathy 7.9%, COPD 5.7%
All-ages prevalence +124.6%
Age-standardised +2.7% (95% UI −0.6 to 5.8)
Leading etiologies: ischaemic HD 33.7%, hypertensive HD 23.8%, other cardiomyopathy 7.9%, COPD 5.7%
Globally, #HeartFailure affected an estimated 56 million people in 2023, with increasing burden largely associated with population growth and aging.
ja.ma/4AVWa0G
ja.ma/4AVWa0G
October 1, 2026 at 8:45 AM
GBD 2023, heart failure: estimated 56.0 million cases in 2023 (24.9 million in 1990)
All-ages prevalence +124.6%
Age-standardised +2.7% (95% UI −0.6 to 5.8)
Leading etiologies: ischaemic HD 33.7%, hypertensive HD 23.8%, other cardiomyopathy 7.9%, COPD 5.7%
All-ages prevalence +124.6%
Age-standardised +2.7% (95% UI −0.6 to 5.8)
Leading etiologies: ischaemic HD 33.7%, hypertensive HD 23.8%, other cardiomyopathy 7.9%, COPD 5.7%
STAREE (NEJM): atorvastatin 40 mg vs placebo, adults ≥70 y without CVD, diabetes or dementia. n = 9971, median 5.9 y
Primary 1, major CV events: HR 0.70 (95% CI 0.61–0.82)
Primary 2, death, dementia or persistent disability: HR 0.94 (0.84–1.05)
Serious AEs: 2.7% vs 2.7%
Primary 1, major CV events: HR 0.70 (95% CI 0.61–0.82)
Primary 2, death, dementia or persistent disability: HR 0.94 (0.84–1.05)
Serious AEs: 2.7% vs 2.7%
October 1, 2026 at 8:43 AM
STAREE (NEJM): atorvastatin 40 mg vs placebo, adults ≥70 y without CVD, diabetes or dementia. n = 9971, median 5.9 y
Primary 1, major CV events: HR 0.70 (95% CI 0.61–0.82)
Primary 2, death, dementia or persistent disability: HR 0.94 (0.84–1.05)
Serious AEs: 2.7% vs 2.7%
Primary 1, major CV events: HR 0.70 (95% CI 0.61–0.82)
Primary 2, death, dementia or persistent disability: HR 0.94 (0.84–1.05)
Serious AEs: 2.7% vs 2.7%